orforglipron
Sign in to saveOrforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018.
~3 min read
Encyclopedic overview
6 sectionsContents
- Mechanism of action
- Clinical trials
- Phase III ACHIEVE-1 trial
- See also
- References
- External links
Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018.
Orforglipron is easier to produce than existing peptide GLP-1 agonists and is expected to be cheaper.
Excerpted from Wikipedia’s “orforglipron” article, available under the CC BY-SA 4.0 licence.